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Are chondroitin 
and glucosamine in 
combination effective 
in the treatment of 
osteoarthritic pain?
Non-steroidal anti-inflammatory drugs today are contraindicated for 
osteoarthritic pain in elderly patients with cardiovascular disease 
due to adverse effects.   An internet review of the evidence regarding 
the use in osteoarthritis of oral chondroitin and glucosamine 
in combination produced three relevant randomised controlled 
trials with valid results.  After critical appraisal for reliability and 
applicability, chondroitin-glucosamine was found to significantly 
reduce pain in moderate knee osteoarthritis, while significantly 
improving disability in mild to moderate cases.   If the results are 
generalisable to osteoarthritis of all joints, combined chondroitin-
glucosamine in purified therapeutic doses should help care for 
osteoarthritis patients safely and at moderate expense.
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Introduction
Osteoarthritis (OA), the commonest 
form of arthritis, is the medical condition 
associated with the highest risk of disabling 
immobility over the age of 65 years when 
the knee joint is involved.1   Beyond 
disability, OA also affects quality of life, 
with consequences on emotional well-
being and body image, relationships, social 
activities and socio-economic status.2
Of non-surgical treatments for OA, 
non-steroidal anti-inflammatory drugs 
(NSAIDs) are effective in reducing pain 
(as is paracetamol) and inflammation3.   
However, besides their well-documented 
adverse effects on the gastrointestinal 
tract,4 some NSAIDs have been said to 
worsen OA through accelerating cartilage 
degeneration or analgesia-associated joint 
overuse.5   Recently NSAIDs have also been 
associated with increased risk of myocardial 
infarction.3   In fact, the latest NSAIDs of 
the selective COX-2 inhibitor group are now 
contraindicated in vascular disease,4 which 
of course is predominant in the elderly.
Therefore, as NSAIDs can no longer 
be used for OA in elderly patients with 
cardiovascular disease, and if paracetamol 
is found to be ineffective, in such cases 
there certainly would be a place for another 
form of oral treatment. Chondroitin and 
glucosamine are such alternative therapies 
for osteoarthritis made popular with 
the general public as a result of media 
publicity.1,6,7
Glucosamine stimulates the production 
of glycosaminoglycan, a constituent of 
joint cartilage, while the degradation 
of glycosaminoglycan is inhibited by 
chondroitin, thus leading to the hypothesis 
of a synergistic effect when these are 
used in combination.7,8   Glucosamine and 
chondroitin thus may be effective in slowing 
the degenerative process of OA as disease-
modifying osteoarthritis drugs, and could 
have an important effect in postponing the 
need for joint replacement in severe OA.7
A review of the evidence was thus 
performed regarding the use of oral 
forms of chondroitin and glucosamine in 
combination as an alternative treatment 
for osteoarthritis, which would effectively 
tackle the pain without causing the 
adverse effects associated with traditional 
analgesics.
Methodology
The review was carried out through an 
internet search of secondary and primary 
sources, followed by a critical evaluation 
of the results. Primary sources consist 
of original research studies, of which 
Randomised Controlled Trials (RCTs) are 
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Author/s	±	Name	 Subjects	 Inclusion	criteria	 Method
Leffler et al.5 34 US Navy males  Chronic pain for at least One group treated with capsules of glucosamine 1500mg/day,
 in their 40s 3 months due to  chondroitin 1200mg/day and manganese 228mg/day, with the
  radiographic mild to  other given placebo capsules, for 8 weeks. Patients then
  moderate degenerative  crossed over to the alternative regimen for an additional
  joint disease of the knee  8 weeks, with the study thus lasting 16 weeks in all*
  and/or lower back
Das & Hammad7 93 patients  Radiographic evidence Intervention group was prescribed capsules of glucosamine
 (aged 45 to 75 years,  of mild to severe 2000mg/day, chondroitin 1600mg/day and manganese
 of both sexes), from  osteoarthritis (OA) 304mg/day, with the other group receiving placebo capsules,
 a single orthopaedic  of the knee and for 6 months
 practice in the USA symptoms for more 
  than 6 months
Rai et al.16 100 out-patients  Clinical and radiological Chondroitin and glucosamine (at unspecified doses) 
 (ages 50 years plus)  OA of the knee to intervention group and placebo capsules
 from an orthopaedic   to control group, for 1 year
 department in 
 north India
Clegg et al.  1583 patients Over 6 months’ 5 groups received one of the following treatments
‘Glucosamine/ (from both sexes, symptoms of for 24 weeks: glucosamine 1500mg/day, chondroitin
chondroitin  40-70 years old)  radiographic 1200mg/day, glucosamine 1500mg/day plus chondroitin
Arthritis  in 16 US centres OA knee 1200mg/day, celecoxib 200mg/day, or placebo
Intervention Trail’ 
(GAIT)6      
*The trial attempted to minimise post-treatment crossover effects through washout periods before data collection (5 weeks for dairy data and 7 weeks for examination data)
Table	1:	Details	of	the	four	evaluated	randomised	double-blind	controlled	trials	 	 	
regarded as the gold standard.   Secondary 
sources comprise reviews or meta-analyses 
of primary studies (normally RCTs).
Secondary	source	search	and	evaluation
The Cochrane Database of Systematic 
Reviews (http://www.cochrane.org/) 
was searched for the combined terms 
“osteoarthritis”, “chondroitin” and 
“glucosamine” in all fields.   Only two 
reviews (by Singh et al.9 and Towheed et 
al.10) looked at the use of chondroitin 
and glucosamine for the treatment of 
osteoarthritis.   However, as the therapies 
were assessed on an individual basis 
(chondroitin and glucosamine respectively) 
and not in combination, they were 
unsuitable for consideration by this study.
Subsequently the Database of Abstracts 
of Reviews of Effects (DARE) (http://
nhscrd.york.ac.uk/) was searched for 
these same combined terms in all fields, 
and produced two hits, namely McAlindon 
et al.11 and Richy et al.12   As these two 
meta-analyses appraised studies of separate 
(not combined) use of chondroitin and 
glucosamine, they too could not be 
considered for this review.   The next 
section will thus focus on the primary 
search for relevant evidence.
Primary	source	search	and	evaluation
A search was performed of Medline 
through PubMed (http://www.pubmed.gov/) 
for the Medical Subject Headings (MeSH) 
terms “Osteoarthritis/therapy”[MeSH] AND 
“Chondroitin/therapeutic use”[MeSH] AND 
“Glucosamine/therapeutic use”[MeSH] 
using the following limits: ‘10 Years, only 
items with abstracts, English, Randomized 
Controlled Trial, Humans’.   This search 
resulted in six randomised controlled 
trials.5-8,13,14   Two other pertinent RCTs15,16 
were identified through a search of the 
Cochrane Central Register of Controlled 
Trials (CENTRAL) 2006 Issue 1 (http://
www.cochrane.org/) using the combined 
terms “osteoarthritis”, “chondroitin” and 
“glucosamine” in an ‘all field’ search.
Of these eight relevant RCTs, four 
were eliminated immediately as three 
did not consider the effect of combined 
glucosamine and chondroitin as oral 
therapy13,15 for radiologically confirmed 
osteoarthritis,8 while the fourth just looked 
for a possible side effect on glycosylated 
haemoglobin levels.14   The remaining four 
trials which were suitable for evaluation are 
described in Table 1.   These four RCTs were 
then critically appraised for the validity, 
reliability and applicability of their results.
Critical	appraisal	of	validity	of	results
The validity of the results of the RCTs 
was critically appraised using questions 
developed by Rosenberg & Donald17 shown 
in Table 2.   Of the four trials, that by Rai 
et al.16 did not account properly for all 
patients who entered the trial and attribute 
them at its conclusion.   Moreover, it was 
the only one of the four studies which 
did not specify the doses of chondroitin 
and glucosamine administered.   As such, 
this study was eliminated from further 
consideration.
Critical	appraisal	of	reliability	
and	applicability	of	results
This critical appraisal of the reliability 
and applicability of the three remaining 
trials is based on the check-list of questions 
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(Rosenberg & Donald)17 shown in Table 3.   
All three RCTs were performed for a minimum 
of 8 weeks and a maximum of 6 months, 
giving enough time for the medication to 
have an effect, and included at least two 
recommended outcome measures18 (see Table 
4 for details).
The Leffler et al.5 study of mild to 
moderate OA showed a statistically 
significant improvement in visual analogue 
scale for pain (p=0.02) for knee and back 
data in subjects in the intervention group.   
This was attributed mainly to the knee data 
which, when examined individually, showed a 
mean reduction in the visual analogue score 
for pain of -26.6% during clinic visits (95% 
CI -53.0% to -0.20%; p=0.048) and -28.6% 
in a diary kept by subjects (95% CI -52.7% 
to -4.50%; p=0.02).
In the Das & Hammad trial7, there 
was a statistically significant drop in the 
Lequesne disability index in subjects with 
mild to moderate OA (N=72) treated with 
chondroitin/glucosamine compared to the 
placebo group, from 10.2 (±0.4) at baseline, 
to 7.2 (±0.6; p=0.003) at 4 months, and 7.4 
(±0.6; p=0.04) at 6 months.
In the GAIT large multi-centre study, 
Clegg et al.6 found that, in subjects with 
moderate to severe OA (N=352), chondroitin 
and glucosamine in combination were 
significantly more effective than placebo 
(24.9 % points higher in the WOMAC pain 
score, p=0.002).   For mild to severe OA, 
combined chondroitin-glucosamine also 
showed a higher rate of response compared 
to placebo than either of its individual 
components, but this improvement did not 
reach significance (when taken as p<0.05).
Are	the	results	valid?	 Leffler	et	al.5	 Das	&	Hammad7	 Rai	et	al.16	 Clegg	et	al.6
1. Was the assignment of patients to treatments randomised? Yes Yes Yes Yes
2. Were all patients who entered the trial properly accounted 
 for and attributed at its conclusion? Yes Yes No Yes
3. Was follow-up complete? Yes Yes Yes Yes
4. Were patients analysed in the groups 
 to which they were randomised? Yes Yes Yes Yes
5. Were patients, health workers and study 
 personnel blinded to treatment? Yes Yes Yes Yes 
6. Were the groups similar at the start of the trial? Yes Yes Yes Yes
7. Aside from the experimental intervention, 
 were the groups treated equally?” Yes Yes Yes Yes
Table	2:	Critical	appraisal	of	result	validity	of	the	relevant	RCTs	based	on	questions	developed	by	Rosenberg	&	Donald17	 	
Are	the	results	reliable?
• How precise was the treatment effect?
• How large was the treatment effect?
Are	the	results	applicable?
• Can the results be applied to my patient care?
• Will the results help me care for my patients?
• Were all clinically important outcomes considered?
• Are the likely benefits worth the potential harms and costs?
Table	3:	Critical	appraisal	of	the	reliability	and	applicability	of	the	relevant	RCTs	
(Rosenberg	&	Donald)17
Outcome	measure	 Used	by
Global pain score for index joint  Clegg et al.6 
(visual analogue or Likert scale) Das & Hammad7
 Leffler et al.5
Pain on walking for index joint  None
(visual analogue or Likert scale)  
Western Ontario and McMaster Universities (WOMAC)  Clegg et al.6
Osteoarthritis Index Pain Subscale  Das & Hammad7
(visual analogue or Likert scale)
Lequesne index (questionnaire-based disability score) Das & Hammad7
 Leffler et al.5
Pain in index joint during activities other than walking  None
(visual analogue or Likert scale)
Table	4:	Outcome	measures	recommended	for	osteoarthritis	trials	by	the	
Osteoarthritis	Research	Society18	and	their	use	by	the	three	appraised	trials
Discussion
When the results of the three RCTs 
are taken together, chondroitin and 
glucosamine in combination were found to:
• significantly reduce pain in mild to 
moderate OA measured by the global pain 
visual analogue scale5, and in moderate 
to severe OA measured by the WOMAC 
Scale;6
• significantly improve disability in mild 
to moderate OA as measured by the 
Lequesne Index.7
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As patients in the community have 
similar characteristics to the subjects within 
the three trials (males and females aged 
over forty, with painful mild, moderate 
or severe osteoarthritis of the knee), the 
results can be applied to such patient care.   
However the quality and standardisation of 
commercially-available food supplements 
such as chondroitin and glucosamine 
are questionable, and thus effects in 
practice may not be equivalent to RCTs’ 
results based upon purified and assayed 
preparations.6,7,19,20
Nevertheless, if the results are taken to 
be generalisable to OA of all joints, and if 
the chondroitin-glucosamine combination 
used in practice is pure and potent, the 
results should help care for patients in 
practice as long as the optimal therapeutic 
doses are used.   This would involve doses 
ranging from glucosamine 1500mg/day and 
chondroitin 1200mg/day5,6 to glucosamine 
2000mg/day and chondroitin 1600mg/day.7
As signs and symptoms of side effects 
were rare and mild, and were similar 
between the intervention and placebo 
groups, the benefit-risk ratio seems 
favourable.   However, one needs to 
consider the adverse effects of long term 
use, such as on diabetes control14, and also 
any effects resulting from drug interactions.  
Regarding financial aspects, chondroitin 
and glucosamine each cost up to $25 each 
month.19   Studies need to be carried out to 
establish if this expense may be considered 
as an investment in view of a possible 
reduction of any expensive management 
options necessitated by complications of 
osteoarthritis.
Conclusion
There are good indications that 
combined oral preparations of chondroitin 
and glucosamine may be effective and quite 
useful in the treatment of osteoarthritis 
due to their safety and moderate expense, 
as long as their purity and potency are 
ensured.   In order to facilitate any possible 
recommendations for their use in clinical 
practice, long-term and larger studies are 
needed to elaborate more definite results 
and investigate their preventive use as 
disease-modifying osteoarthritis drugs.
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